Cost considerations in the use of anaesthetic drugs

PharmacoEconomics

Volumn 19, Issue 5, 2001, Pages 469-481

  Smith, Ian ^a,b  

^a KEELE UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; ANTIEMETIC AGENT; DESFLURANE; ENFLURANE; GENERIC DRUG; HALOTHANE; ISOFLURANE; NITRIC OXIDE; ONDANSETRON; PROPOFOL; SEVOFLURANE;

BUDGET; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; GENERAL ANESTHESIA; HEALTH CARE COST; HUMAN; INTRAVENOUS ANESTHESIA; MEDICAL DECISION MAKING; POSTOPERATIVE NAUSEA AND VOMITING; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

EID: 0035001645     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200119050-00003     Document Type: Review

References (50)

1. Hawkes C, Miller D, Martineau R, et al. Evaluation of cost minimization strategies of anaesthetic drugs in a tertiary care hospital. Can J Anaesth 1994; 41: 894-901
2. Macario A, Vitez TS, Dunn B, et al. Where are the costs in perioperative care? Analysis of hospital costs and charges for inpatient surgical care. Anesthesiology 1995; 83: 1138-44
3. Rowe WL. Economics and anaesthesia. Anaesthesia 1998; 53: 782-8
4. Sperry RJ. Principles of economic analysis. Anesthesiology 1997; 86: 1197-205
5. Crozier TA, Kettler D. Cost effectiveness of general anaesthesia: inhalation vs i.v. [editorial]. Br J Anaesth 1999; 83: 547-9
6. Johnstone RE, Martinec CL. Costs of anesthesia. Anesth Analg 1993; 76: 840-8
7. Bach A, Motsch J. Infectious risks associated with the use of propofol [review]. Acta Anaesthesiol Scand 1996; 40: 1189-96
8. Propofol. Manufacturer's data sheet. AstraZeneca: Kings Langley, Hertfordshire: 1998-1999
9. Logan M. Breathing systems: effect of fresh gas flow rate on enflurane consumption. Br J Anaesth 1994; 73: 775-8
10. Boldt J, Jaun N, Kumle B, et al. Economic considerations of the use of new anesthetics: a comparison of propofol, sevoflurane, desflurane, and isoflurane. Anesth Analg 1998; 86: 504-9
11. Laster MJ, Fang Z, Eger II EI. Specific gravities of desflurane, enflurane, halothane, isoflurane, and sevoflurane. Anesth Analg 1994; 78: 1152-3
12. Pedersen FM, Nielsen J, Ibsen M, et al. Low-flow isoflurane-nitrous oxide anaesthesia offers substantial economic advantages over high-and medium-flow isoflurane-nitrous oxide anaesthesia. Acta Anaesthesiol Scand 1993; 37: 509-12
13. Perkins R, Meakin G. Economics of low-flow anaesthesia in children. Anaesthesia 1996; 51: 1089-92
14. Suttner S, Boldt J. Low-flow anaesthesia: does it have potential pharmacoeconomic consequences? Pharmacoeconomics 2000; 17: 585-90
15. Body SC, Fanikos J, DePeiro D, et al. Individualized feedback of volatile agent use reduces fresh gas flow rate, but fails to favorably affect agent choice. Anesthesiology 1999; 90: 1171-5
16. Smith I. Costs of sevoflurane and propofol anaesthesia. In reply [letter]. Br J Anaesth 2000; 84: 418
17. Dexter F, Macario A, Manberg PJ, et al. Computer simulation to determine how rapid anesthetic recovery protocols to decrease the time for emergence or increase the Phase I Postanesthesia care unit bypass rate affect staffing of an ambulatory surgery center. Anesth Analg 1999; 88: 1053-63
18. Lubarsky DA. The successful implementation of pharmaceutical practice guidelines? Far from convincing! In reply [letter]. Anesthesiology 1997; 87: 1584
19. Lubarsky DA. Pharmaceutical practice guidelines: do they actually cost money? In reply [letter]. Anesthesiology 1998; 89: 270-1
20. Marais ML, Maher MW, Wetchler BV, et al. Reduced demands on recovery room resources with propofol (Diprivan) compared to thiopental-isoflurane. Anesth Rev 1989; 16 (1): 29-40
21. Langevin PB. Propofol containing sulfite - potential for injury [letter]. Chest 1999; 116: 1140-1
22. Watcha MF, White PF. Economics of anesthetic practice. Anesthesiology 1997; 86: 1170-96
23. Sung YF, Reiss N, Tillette T. The differential cost of anesthesia and recovery with propofol-nitrous oxide anesthesia versus thiopental sodium-nitrous oxide anesthesia. J Clin Anesth 1991; 3: 391-4
24. Smith I, White PF, Nathanson M, et al. Propofol: an update on its clinical use. Anesthesiology 1994; 81: 1005-43
25. Dexter F, Coffin S, Tinker JH. Decreases in anesthesia-controlled time cannot permit one additional surgical operation to be reliably scheduled during the workday. Anesth Analg 1995; 81: 1263-8
26. Overdyk FJ, Harvey SC, Fishman RL, et al. Successful strategies for improving operating room efficiency at academic institutions. Anesth Analg 1998; 86: 896-906
27. Heidvall M, Hein A, Davidson S, et al. Cost comparison between three different general anaesthetic techniques for elective arthroscopy of the knee. Acta Anaesthesiol Scand 2000; 44: 157-62
28. Smith I, Terhoeve PA, Hennart D, et al. A multicentre comparison of the costs of anaesthesia with sevoflurane or propofol. Br J Anaesth 1999; 83: 564-70
29. Sneyd JR, Carr A, Byrom WD, et al. A meta-analysis of nausea and vomiting following maintenance of anaesthesia with propofol or inhalational agents. Eur J Anaesthesiol 1998; 15: 433-45
30. Tramèr M, Moore A, McQuay H. Propofol anaesthesia and postoperative nausea and vomiting: quantitative systemic review of randomized controlled studies. Br J Anaesth 1997; 78: 247-55
31. Watcha MF, Smith I. Cost-effectiveness analysis of antiemetic therapy for ambulatory surgery. J Clin Anesth 1994; 6: 370-7
32. Tang J, Watcha MF, White PF. A comparison of costs and efficacy of ondansetron and droperidol as prophylactic antiemetic therapy for elective outpatient gynecologic procedures. Anesth Analg 1996; 83: 304-13
33. Watcha MF. The cost-effective management of postoperative nausea and vomiting. Anesthesiology 2000; 92: 931-3
34. Carroll NV, Miederhoff P, Cox FM, et al. Costs incurred by outpatient surgical centers in managing postoperative nausea and vomiting. J Clin Anesth 1994; 6: 364-9
35. Tang J, Wang B, White PF, et al. The effect of timing of ondansetron administration on its efficacy, cost-effectiveness, and cost-benefit as a prophylactic antiemetic in the ambulatory setting. Anesth Analg 1998; 86: 274-82
36. Ding Y, Fredman B, White PF. Recovery following outpatient anesthesia: use of enflurane versus propofol. J Clin Anesth 1993; 5: 447-50
37. Marshall CA, Jones RM, Bajorek PK, et al. Recovery characteristics using isoflurane or propofol for maintenance of anaesthesia: a double-blind controlled trial. Anaesthesia 1992; 47: 461-6
38. Rapp SE, Conahan TJ, Pavlin DJ, et al. Comparison of desflurane with propofol in outpatients undergoing peripheral orthopedic surgery. Anesth Analg 1992; 75: 572-9
39. Van Hemelrijck J, Smith I, White PF. Use of desflurane for outpatient anesthesia: a comparison with propofol and nitrous oxide. Anesthesiology 1991; 75: 197-203
40. Fredman B, Nathanson MH, Smith I, et al. Sevoflurane for outpatient anesthesia: a comparison with propofol. Anesth Analg 1995; 81: 823-8
41. Green G, Jonsson L. Nausea: the most important factor determining length of stay after ambulatory anaesthesia: a comparative study of isoflurane and/or propofol techniques. Acta Anaesthesiol Scand 1993; 37: 742-6
42. Smith I, Thwaites AJ. Target-controlled propofol vs. sevoflurane: a double-blind, randomised comparison in day-case anaesthesia. Anaesthesia 1999; 54: 745-52
43. Tang J, Chen L, White PF, et al. Recovery profile, costs, and patient satisfaction with propofol and sevoflurane for fasttrack office-based anesthesia. Anesthesiology 1999; 91: 253-61
44. Fisher DM. The 'big little problem' of postoperative nausea and vomiting: do we know the answer yet [editorial]? Anesthesiology 1997; 87: 1271-3
45. Fisher DM. Surrogate endpoints: are they meaningful [editorial]? Anesthesiology 1994; 81: 795-6
46. Scuderi PE, James RL, Harris L, et al. Antiemetic prophylaxis does not improve outcomes after outpatient surgery when compared to symptomatic treatment. Anesthesiology 1999; 90: 360-71
47. Johnstone RE, Jozefczyk KG. Costs of anesthetic drugs: experiences with a cost education trial. Anesth Analg 1994; 78: 766-71
48. Lubarsky DA, Glass PSA, Ginsberg B, et al. The successful implementation of pharmaceutical practice guidelines: analysis of associated outcomes and cost savings. Anesthesiology 1997; 86: 1145-60
49. Bailey PL, Egan TD. The successful implementation of pharmaceutical practice guidelines? Far from convincing [letter]! Anesthesiology 1997; 87: 1583-4
50. Orkin FK. Meaningful cost reduction: penny wise, pound foolish [editorial]. Anesthesiology 1995; 83: 1135-7